... from data in the RCT. The survival of patients receiving ASC/BSC was calculated from the survival of the patients in the cetuximab monotherapy arm of the RCT. The data from the monotherapy arm ... appraisal guidance 118 20 of the drugs were tolerated willingly because of the perceived benefit, whereas for others the side-effect profile may be more of a consideration. The Committee heard from ... agreed that fitness, rather than age, is the primary factor when considering whether chemotherapy is appropriate. The Committee therefore agreed that the patients included in the NICE technology...